HomeCompareVRNA vs EPRT

VRNA vs EPRT: Dividend Comparison 2026

VRNA yields 1.87% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $41.0K in total portfolio value
10 years
VRNA
VRNA
● Live price
1.87%
Share price
$106.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.4K
Annual income
$211.14
Full VRNA calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — VRNA vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRNAEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRNA + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRNA pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRNA
Annual income on $10K today (after 15% tax)
$159.01/yr
After 10yr DRIP, annual income (after tax)
$179.47/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,735.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRNA + EPRT for your $10,000?

VRNA: 50%EPRT: 50%
100% EPRT50/50100% VRNA
Portfolio after 10yr
$42.9K
Annual income
$6,525.93/yr
Blended yield
15.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

VRNA
Analyst Ratings
9
Buy
5
Hold
Consensus: Buy
Price Target
$75.73
-29.2% upside vs current
Range: $26.00 — $170.00
Altman Z
111.3
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRNA buys
0
EPRT buys
0
No recent congressional trades found for VRNA or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRNAEPRT
Forward yield1.87%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$22.4K$63.4K
Annual income after 10y$211.14$12,840.73
Total dividends collected$2.0K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$75.73$35.50

Year-by-year: VRNA vs EPRT ($10,000, DRIP)

YearVRNA PortfolioVRNA Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,887$187.07$11,205$505.18$318.00EPRT
2$11,840$190.34$12,672$682.46$832.00EPRT
3$12,862$193.45$14,490$930.48$1.6KEPRT
4$13,958$196.41$16,786$1,282.69$2.8KEPRT
5$15,135$199.21$19,753$1,791.56$4.6KEPRT
6$16,396$201.87$23,677$2,541.64$7.3KEPRT
7$17,748$204.38$29,008$3,672.99$11.3KEPRT
8$19,197$206.77$36,463$5,425.08$17.3KEPRT
9$20,750$209.02$47,238$8,221.57$26.5KEPRT
10$22,414$211.14$63,385$12,840.73$41.0KEPRT

VRNA vs EPRT: Complete Analysis 2026

VRNAStock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Full VRNA Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this VRNA vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRNA vs SCHDVRNA vs JEPIVRNA vs OVRNA vs KOVRNA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.